Cell and Gene Therapy Third-Party Logistics Market Size & Growth Forecast 2027–2036, By Segments (Type, Product, End-use, Temperature Range, Therapeutic Area), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Cell and Gene Therapy Third-Party Logistics Market size stood at USD 12.79 billion in 2026 and is predicted to grow at a 11.44% CAGR from 2027 to 2036, attaining USD 37.78 billion by 2036. The industry revenue for 2027 is assessed at USD 14.06 billion.
Get more details on this report
Request Free Sample ReportCell and Gene Therapy Third-Party Logistics Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 41.18% of the market in 2026, supported by an established advanced therapy ecosystem, sophisticated healthcare infrastructure, and demand for specialized, temperature-controlled, traceable therapy shipments.
- Asia Pacific is projected to grow fastest as biotechnology investments, clinical research, and advanced therapy development expand, alongside improvements in cold-chain infrastructure, specialized packaging, and shipment monitoring capabilities.
Segment Momentum
- Clinical logistics accounts for 81.66% of market share in 2026 because investigational therapies require specialized handling, temperature management, chain-of-custody controls, and time-critical transportation. These requirements make experienced logistics providers essential to maintaining product integrity throughout clinical development.
- The commercial segment is expected to grow fastest as more therapies move into routine use. Expanding distribution needs are increasing demand for scalable logistics networks, specialized storage, inventory management, shipment visibility, and coordinated deliveries to treatment centers.
Market Expansion Drivers
- Growth in CGT clinical pipelines.
- Specialized cold-chain expansion.
- Ultra-low temperature logistics.
Leading Market Participants
- Major players in the cell and gene therapy third-party logistics market include Marken (USA), World Courier (USA), Cryoport (USA), DHL (Germany), UPS Healthcare (USA), FedEx (USA), QuickSTAT (USA), Kuehne+Nagel (Switzerland), CEVA Logistics (France), Biocair (UK).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 12.79 billion
- 2027 Estimated Market Size: USD 14.06 billion
- Projected Market Size: USD 37.78 billion by 2036
- Growth Forecast: 11.44% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Type (Clinical) | Product (Cell Therapies) | End-use (Biopharmaceutical Companies) | Temperature Range (Ambient Storage) | Therapeutic Area (Oncology)
- Emerging Opportunity Segment: Type (Commercial) | Product (Cell Therapies) | End-use (Biopharmaceutical Companies) | Temperature Range (Cryogenic Storage) | Therapeutic Area (Oncology)
Market Growth Drivers and Industry Trends
Growth in CGT clinical pipelines
The expansion of cell and gene therapy clinical pipelines is creating greater demand for specialized third-party logistics capabilities capable of managing highly sensitive biological materials. These therapies often require carefully coordinated collection, processing, storage, and delivery workflows, with strict requirements for traceability and handling conditions. As more therapies progress through clinical development, logistics providers are increasingly required to support complex supply chains involving multiple locations, specialized facilities, and time-sensitive movements.
Specialized cold-chain expansion
The expansion of specialized cold-chain infrastructure is being driven by the unique stability requirements of cell and gene therapy products. Unlike conventional pharmaceuticals, many advanced therapies can be highly sensitive to temperature fluctuations, handling conditions, and transportation delays. Investment in validated packaging, monitored transportation, specialized storage facilities, and coordinated logistics processes is therefore supporting the development of more sophisticated cold-chain networks tailored to advanced therapy requirements.
Ultra-low temperature logistics
The increasing use of ultra-low temperature storage and transportation is strengthening demand for logistics services designed to preserve the integrity of temperature-sensitive cell and gene therapy materials. Such therapies may require tightly controlled conditions from manufacturing through administration, making continuous temperature monitoring, validated handling procedures, contingency planning, and rapid intervention essential. The need to maintain product quality throughout these demanding transportation cycles is encouraging greater reliance on specialized logistics providers with advanced cold-chain capabilities.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Growth in CGT clinical pipelines | 3.5% | Short term (≤ 2 yrs) | North America; Europe | Medium | Moderate |
| Specialized cold-chain expansion | 3% | Medium term (2–5 yrs) | Europe; Asia Pacific | Medium | Moderate |
| Ultra-low temperature logistics | 2% | Long term (5+ yrs) | North America; Asia Pacific | High | Slow |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America accounted for a 41.18% share in 2026 and represented the largest regional market, backed by its established cell and gene therapy ecosystem, advanced healthcare infrastructure, and strong demand for specialized logistics services. The growing development and commercialization of temperature-sensitive and highly personalized therapies is increasing the need for reliable transportation, specialized packaging, real-time monitoring, and controlled handling throughout the supply chain. Strong investment in advanced healthcare logistics infrastructure and the presence of sophisticated clinical research and manufacturing networks are further supporting market development. Increasing demand for compliant and traceable logistics solutions is encouraging the adoption of specialized third-party logistics services capable of managing complex therapy shipments.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is anticipated to be the fastest-growing region, driven by expanding healthcare infrastructure, increasing investments in biotechnology and advanced therapies, and growing clinical research activity. The region is witnessing rising demand for specialized logistics capabilities as cell and gene therapy development expands and healthcare systems increasingly adopt innovative treatment approaches. Improvements in cold-chain infrastructure, temperature-controlled transportation, specialized packaging, and shipment monitoring are supporting more reliable movement of sensitive therapeutic materials. Growing efforts to strengthen pharmaceutical supply chains and improve regulatory and manufacturing capabilities are also encouraging third-party logistics adoption. In addition, increasing collaboration across biotechnology, healthcare, and logistics sectors is creating opportunities for integrated supply-chain services, positioning Asia Pacific as a rapidly expanding market for cell and gene therapy third-party logistics.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Specialized Therapy LogisticsThe U.S. market prioritizes highly controlled logistics for time-sensitive cell and gene therapies, including cryogenic transport, chain-of-identity management, and real-time shipment monitoring. Third-party logistics providers increasingly differentiate through specialized handling infrastructure, integrated technology, and capabilities supporting complex clinical and commercial therapy distribution.
Germany 🇩🇪
Precision Cold-Chain LogisticsGermany emphasizes specialized logistics capable of maintaining stringent temperature, traceability, and handling requirements for advanced therapies. Market priorities include validated cryogenic transportation, chain-of-custody visibility, regulatory compliance, and coordination among manufacturers, clinical centers, and specialized treatment facilities across European distribution networks.
Japan 🇯🇵
Controlled Therapy DistributionJapan’s cell and gene therapy logistics market requires precise coordination of temperature-sensitive materials, patient-specific shipments, and treatment schedules. Providers focus on validated cold-chain processes, shipment visibility, documentation, and reliable handoffs between manufacturers and healthcare institutions as advanced therapies move toward broader clinical use.
South Korea 🇰🇷
Advanced Therapy Cold ChainSouth Korea’s market is developing around specialized logistics for increasingly sophisticated cell and gene therapy workflows. Third-party providers prioritize cryogenic handling, digital tracking, chain-of-identity controls, and coordinated delivery to clinical sites, with operational reliability becoming increasingly important as advanced therapies progress through commercialization.
France 🇫🇷
European Therapy LogisticsFrance’s market priorities center on compliant, traceable distribution of advanced therapies across manufacturers, hospitals, and clinical networks. Logistics providers emphasize temperature-controlled transportation, chain-of-custody integrity, validated handling procedures, and coordination with healthcare facilities to support therapies requiring highly synchronized delivery and administration.
Italy 🇮🇹
Clinical Supply CoordinationItaly’s cell and gene therapy logistics requirements are centered on dependable coordination between therapy developers, specialized treatment centers, and clinical supply networks. Providers prioritize controlled-temperature handling, shipment traceability, regulatory documentation, and flexible delivery processes capable of supporting patient-specific and time-critical therapy workflows.
Cell and Gene Therapy Third-Party Logistics Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Clinical (Largest Segment) vs Commercial (Fastest-Growing Segment)
The clinical type segment accounted for 81.66% share of the cell and gene therapy third-party logistics market in 2026, supported by the specialized logistics requirements associated with investigational cell and gene therapies throughout clinical development. Clinical-stage materials often require tightly controlled transportation, specialized handling, temperature management, chain-of-custody procedures, and coordination across treatment centers, laboratories, and manufacturing facilities. The complexity of moving highly sensitive biological materials during clinical trials increases the need for specialized third-party logistics providers capable of maintaining product integrity while supporting time-critical delivery schedules. As cell and gene therapy pipelines expand and clinical development activities become more geographically distributed, demand for reliable logistics solutions tailored to clinical applications is expected to remain strong.
The commercial type segment is expected to register the fastest growth, driven by the increasing transition of cell and gene therapies from clinical development into routine commercial use. As more therapies reach broader patient populations, logistics requirements are expanding beyond trial-related shipments toward scalable distribution networks capable of supporting recurring deliveries, specialized storage, inventory management, and coordinated distribution to treatment centers. The growing commercialization of personalized and temperature-sensitive therapies is also increasing the importance of end-to-end visibility, rapid delivery, and stringent handling procedures, creating significant opportunities for third-party logistics providers serving the commercial cell and gene therapy supply chain.
Product Segment Analysis: Cell Therapies (Largest & Fastest-Growing Segment)
The cell therapies product segment represented the largest share of the cell and gene therapy third-party logistics market in 2026 and is also expected to experience the fastest growth, reflecting the highly specialized logistics requirements associated with transporting living cellular materials. Cell therapies often require carefully controlled handling, storage, and transportation conditions to preserve product quality and viability throughout the supply chain. Their individualized nature can also create complex logistics flows involving collection sites, manufacturing facilities, testing laboratories, and treatment centers, increasing the need for coordinated third-party logistics services. As development and commercialization of cell-based treatments expand, logistics providers are increasingly required to support time-sensitive transportation, chain-of-custody management, specialized packaging, temperature control, and real-time shipment visibility. These requirements strengthen the role of specialized logistics partners and support sustained demand for cell therapy logistics services across the evolving cell and gene therapy supply chain.
End-use Segment Analysis: Biopharmaceutical Companies (Largest & Fastest-Growing Segment)
The biopharmaceutical companies end-use segment represented the largest share of the cell and gene therapy third-party logistics market in 2026 and is also expected to grow at the fastest pace, driven by the expanding development, manufacturing, and commercialization of advanced cell and gene therapies. Biopharmaceutical companies rely on specialized third-party logistics providers to manage complex transportation requirements across research, clinical development, manufacturing, and commercial distribution stages. The sensitivity of these therapies increases the importance of controlled environments, specialized packaging, traceability, rapid transportation, and coordinated delivery processes, particularly when products must move between geographically dispersed facilities and treatment centers. As biopharmaceutical companies expand their cell and gene therapy pipelines and move more products toward commercialization, their need for scalable and specialized logistics capabilities is expected to increase, supporting strong demand for third-party logistics services tailored to advanced therapies.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Clinical, Commercial | Clinical | Commercial |
| Product | Cell Therapies, Gene Therapies | Cell Therapies | Cell Therapies |
| End-use | Biopharmaceutical Companies, CDMOs/CMOs, Others | Biopharmaceutical Companies | Biopharmaceutical Companies |
| Temperature Range | Ambient Storage, Refrigerated Storage, Ultra-Low Temperature Storage, Cryogenic Storage | Ambient Storage | Cryogenic Storage |
| Therapeutic Area | Oncology, Neurology, Cardiovascular Diseases, Ophthalmology, Infectious Diseases, Others | Oncology | Oncology |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
The competitive landscape for cell and gene therapy third-party logistics is defined by product integrity, shipment traceability, and coordination across complex treatment supply chains. Cryogenic and ultra-low-temperature capabilities require validated packaging, dependable monitoring, and effective contingency procedures tailored to individual therapies. Real-time tracking strengthens shipment visibility, but its value depends on reliable data, documented chain-of-custody controls, and timely management of deviations. Autologous therapies introduce additional complexity because collection, manufacturing, release, and delivery must be coordinated around patient-specific timelines without compromising identity controls or product quality. Cross-border movements further require expertise in permits, customs documentation, and jurisdiction-specific biological-material requirements. Providers that combine validated temperature management with responsive coordination, regulatory competence, and end-to-end traceability are better equipped to serve time-sensitive advanced therapy supply chains.
Key companies in the cell and gene therapy third-party logistics market:
- Marken (USA)
- World Courier (USA)
- Cryoport (USA)
- DHL (Germany)
- UPS Healthcare (USA)
- FedEx (USA)
- QuickSTAT (USA)
- Kuehne+Nagel (Switzerland)
- CEVA Logistics (France)
- Biocair (UK)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Marken (USA) | |||||||
| World Courier (USA) | |||||||
| Cryoport (USA) | |||||||
| DHL (Germany) | |||||||
| UPS Healthcare (USA) | |||||||
| FedEx (USA) | |||||||
| QuickSTAT (USA) | |||||||
| Kuehne+Nagel (Switzerland) | |||||||
| CEVA Logistics (France) | |||||||
| Biocair (UK) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| DHL | March 2025 | DHL acquired U.S.-based pharmaceutical logistics firm CryoPDP to strengthen its life sciences and healthcare logistics capabilities. CryoPDP provides temperature-controlled shipping, storage, and packaging services for pharmaceutical and biotech companies, expanding DHL’s supply chain capabilities relevant to specialized cell and gene therapy logistics. |
| Cardinal Health | January 2025 | Cardinal Health launched Advanced Therapy Connect, an integrated ordering platform designed specifically for cell and gene therapies under its Advanced Therapy Solutions division. The platform strengthens Cardinal Health’s specialized infrastructure for managing ordering requirements associated with advanced therapies and supports the development of dedicated logistics and supply-chain capabilities. |
| Alcura | August 2024 | Alcura, a Cencora company, received a Manufacturing and Importation Authorization (MIA) license from the Spanish Agency of Medicines and Medical Devices. The authorization enabled Alcura to provide import, storage, and Qualified Person (QP) Batch Certification services for investigational and commercial cell and gene therapy products, expanding its specialized handling capabilities. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Cell and Gene Therapy Third-Party Logistics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Shipment Mode | Air Freight, Road Transportation, Sea Freight, Multimodal Transportation |
| Logistics Service Model | Transportation Services, Warehousing and Storage, Value-Added Logistics Services |
| Delivery Model | Direct-to-Site Delivery, Hub-and-Spoke Distribution, Centralized Distribution |
Cell and Gene Therapy Third-Party Logistics Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Clinical Trial Logistics Strategy |
|
| Commercial Launch Logistics Readiness |
|
| Chain-of-Custody & Traceability |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the market size of the cell and gene therapy third-party logistics market?
What is the projected value of the cell and gene therapy third-party logistics industry by 2036?
How is the expansion of cell and gene therapy pipelines reshaping logistics requirements?
Why are specialized cold-chain capabilities becoming critical to cell and gene therapy logistics?
Why does the clinical segment dominate cell and gene therapy third-party logistics?
How is the commercial segment creating growth opportunities in cell and gene therapy logistics?
How does North America maintain its leadership in cell and gene therapy third-party logistics?
What is accelerating cell and gene therapy logistics growth in Asia Pacific?
Which companies are driving growth in the cell and gene therapy third-party logistics landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook